Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19056056 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID MODIFICATIONS | February 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 18933499 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18933567 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18933750 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18933645 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18909918 | MODIFIED DOUBLE-STRANDED RNA AGENTS | October 2024 | April 2025 | Allow | 6 | 1 | 0 | No | No |
| 18889137 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | September 2024 | February 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18885005 | Compositions and Methods Using CPG Oligonucleotides | September 2024 | April 2025 | Allow | 7 | 1 | 1 | No | No |
| 18814067 | MODIFIED DOUBLE-STRANDED RNA AGENTS | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18807591 | COMPOSITIONS AND METHODS FOR INHIBITING LPA EXPRESSION | August 2024 | November 2024 | Allow | 3 | 0 | 1 | No | No |
| 18805534 | TUNING CASCADE ASSAY KINETICS VIA MOLECULAR DESIGN | August 2024 | January 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18805023 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | August 2024 | May 2025 | Allow | 9 | 1 | 1 | No | No |
| 18797394 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | August 2024 | March 2025 | Allow | 7 | 1 | 1 | No | No |
| 18834523 | Recombinant Humanized Collagen Type I Alpha-1 (rhCol1A1), and Expression Vector and Use Thereof | July 2024 | April 2025 | Allow | 8 | 1 | 0 | No | No |
| 18777597 | SPLIT COMPLEMENTARY BASE EDITING SYSTEMS BASED ON BIMOLECULAR DEAMINASES AND USES THEREOF | July 2024 | April 2025 | Allow | 9 | 0 | 1 | Yes | No |
| 18743724 | RECOMBINANT PARTICLE PROTEIN PRODUCT SUITABLE FOR INDUSTRIAL PRODUCTION AND PREPARATION METHOD THEREFOR | June 2024 | May 2025 | Allow | 11 | 2 | 0 | Yes | No |
| 18744370 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERY OF MRNA AND LONG NUCLEIC ACIDS | June 2024 | March 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18669712 | ENDONUCLEASE SYSTEMS | May 2024 | May 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18612868 | DETECTION OF NUCLEIC ACID AND NON-NUCLEIC ACID TARGET MOLECULES | March 2024 | July 2024 | Allow | 4 | 1 | 0 | No | No |
| 18604547 | Inducible Promoter for Rice Expression System, Synthetic Biological Platform and Use Thereof | March 2024 | March 2025 | Allow | 12 | 2 | 0 | No | No |
| 18597673 | RIBOSWITCH MODULATED GENE THERAPY FOR RETINAL DISEASES | March 2024 | December 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18594132 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | March 2024 | October 2024 | Allow | 8 | 2 | 0 | No | No |
| 18591645 | GENETICALLY MODIFIED CELL LINES FOR METABOLIC STUDIES | February 2024 | March 2025 | Abandon | 12 | 1 | 0 | No | No |
| 18591760 | GENETICALLY MODIFIED CELL LINES FOR METABOLIC STUDIES | February 2024 | March 2025 | Abandon | 12 | 1 | 0 | No | No |
| 18586689 | COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | February 2024 | January 2025 | Allow | 11 | 1 | 0 | No | No |
| 18586417 | TUNING CASCADE ASSAY KINETICS VIA MOLECULAR DESIGN | February 2024 | August 2024 | Allow | 5 | 1 | 1 | No | No |
| 18430378 | METHOD FOR PRECISELY PREPARING CIRCULAR RNA WITH ANABAENA INTRON SELF-CLEAVING RIBOZYME | February 2024 | August 2024 | Allow | 6 | 1 | 0 | No | No |
| 18428353 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) | January 2024 | April 2025 | Allow | 15 | 0 | 1 | No | No |
| 18425204 | SEQUENCE SPECIFIC ANTIMICROBIALS | January 2024 | January 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18418781 | METHODS FOR SEQUENCING SAMPLES | January 2024 | November 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18418774 | METHODS FOR SEQUENCING SAMPLES | January 2024 | October 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18410136 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | January 2024 | May 2024 | Allow | 4 | 1 | 0 | No | No |
| 18393974 | ADAPTER FOR USE IN A PLANETARY MIXER | December 2023 | April 2025 | Allow | 16 | 3 | 0 | No | No |
| 18392905 | CASZ COMPOSITIONS AND METHODS OF USE | December 2023 | December 2024 | Allow | 12 | 1 | 1 | No | No |
| 18393408 | miRNA Switches for RNA-Triggered Control of RNA Interference | December 2023 | March 2025 | Allow | 15 | 3 | 0 | Yes | No |
| 18390233 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | December 2023 | June 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18543966 | COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOF | December 2023 | February 2025 | Abandon | 14 | 2 | 1 | No | No |
| 18534974 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | December 2023 | June 2024 | Allow | 6 | 1 | 0 | No | No |
| 18534489 | METHODS AND COMPOSITIONS FOR SIMULTANEOUS EDITING OF BOTH STRANDS OF A TARGET DOUBLE-STRANDED NUCLEOTIDE SEQUENCE | December 2023 | March 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18533538 | METHODS FOR SEQUENCING SAMPLES | December 2023 | October 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18532043 | CONTAMINATION CONTROL WHEN GROWING YEASTS | December 2023 | January 2025 | Allow | 13 | 5 | 0 | Yes | No |
| 18523558 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE | November 2023 | May 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18518914 | TUNING CASCADE ASSAY KINETICS VIA MOLECULAR DESIGN | November 2023 | February 2024 | Allow | 3 | 1 | 1 | Yes | No |
| 18518177 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | November 2023 | February 2025 | Allow | 15 | 3 | 1 | Yes | No |
| 18515531 | MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes | November 2023 | May 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18512068 | APPLICATION OF PROKARYOTIC ARGONAUTE PROTEIN WITH ONLY RNA TARGET CLEAVAGE ACTIVITY IN RNA EDITING | November 2023 | June 2024 | Allow | 7 | 1 | 0 | No | No |
| 18504548 | GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR) | November 2023 | June 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18504827 | MICROORGANISMS AND USES THEREOF | November 2023 | January 2025 | Abandon | 14 | 1 | 1 | No | No |
| 18501446 | ADAPTER FOR USE IN A PLANETARY MIXER | November 2023 | August 2024 | Allow | 9 | 2 | 0 | Yes | No |
| 18495420 | NON-TOXIC CAS9 ENZYME AND APPLICATION THEREOF | October 2023 | August 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18491658 | Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18488261 | NOVEL CRISPR ENZYMES AND SYSTEMS | October 2023 | November 2024 | Allow | 13 | 2 | 1 | No | No |
| 18487338 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18487744 | SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE) | October 2023 | December 2023 | Allow | 2 | 1 | 0 | No | No |
| 18483663 | COMPOUNDS AND METHODS FOR MODULATING SCN2A | October 2023 | October 2024 | Allow | 12 | 2 | 0 | No | No |
| 18377294 | DETECTION OF NUCLEIC ACID AND NON-NUCLEIC ACID TARGET MOLECULES | October 2023 | March 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18375415 | DELIVERY OF THERAPEUTICS IN VIVO VIA A CRISPR-BASED CASCADE SYSTEM | September 2023 | April 2024 | Allow | 7 | 2 | 0 | Yes | No |
| 18477069 | PHAGE-DERIVED PARTICLES FOR IN SITU DELIVERY OF DNA PAYLOAD INTO C. ACNES POPULATION | September 2023 | February 2024 | Allow | 4 | 1 | 1 | No | No |
| 18372823 | ANTIBODY-EVADING VIRUS VECTORS | September 2023 | April 2024 | Allow | 6 | 1 | 1 | No | No |
| 18372098 | COMPOSITIONS OF MATTER FOR DETECTION ASSAYS | September 2023 | February 2024 | Allow | 5 | 2 | 0 | No | No |
| 18472824 | ENGINEERED RETRONS AND METHODS OF USE | September 2023 | March 2024 | Allow | 6 | 0 | 0 | Yes | No |
| 18371493 | Method for establishing biological model on joint toxicity of Caenorhabditis elegans and application thereof | September 2023 | June 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18467392 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | September 2023 | March 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18467428 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | September 2023 | March 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18463079 | PANCREATIC CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | September 2023 | August 2024 | Allow | 12 | 0 | 0 | No | No |
| 18457276 | ENGINEERED ADENOSINE DEAMINASES AND BASE EDITORS THEREOF | August 2023 | August 2024 | Allow | 12 | 1 | 1 | Yes | No |
| 18451315 | CRISPR ENZYMES AND SYSTEMS | August 2023 | June 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18449850 | TARGETED TRANS-SPLICING USING CRISPR/CAS13 | August 2023 | January 2025 | Allow | 17 | 2 | 2 | Yes | No |
| 18449230 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC GRANULOMATOUS DISEASE | August 2023 | July 2024 | Allow | 11 | 1 | 1 | Yes | No |
| 18448713 | EXOSOME-TARGETED DNA VACCINE | August 2023 | February 2025 | Allow | 19 | 2 | 0 | No | No |
| 18447536 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | August 2023 | February 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18447681 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | August 2023 | June 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18447515 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | August 2023 | February 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18446743 | Methods for Treatment of Alport Syndrome | August 2023 | March 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18365787 | Novel Structurally Designed shRNAs | August 2023 | February 2025 | Allow | 19 | 1 | 0 | No | No |
| 18362675 | Compositions and Methods for Kallikrein (KLKB1) Gene Editing | July 2023 | May 2025 | Abandon | 22 | 3 | 1 | Yes | No |
| 18361772 | PLATELETS AS DELIVERY AGENTS | July 2023 | May 2025 | Allow | 21 | 1 | 0 | No | No |
| 18356906 | METHODS FOR SEQUENCING SAMPLES | July 2023 | September 2024 | Allow | 14 | 2 | 0 | Yes | No |
| 18356900 | METHODS FOR SEQUENCING SAMPLES | July 2023 | March 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18356961 | TREATMENT OF MUCOPOLYSACCHARIDOSIS II WITH RECOMBINANT HUMAN IDURONATE-2-SULFATASE (IDS) | July 2023 | March 2024 | Allow | 8 | 1 | 0 | No | No |
| 18356013 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | July 2023 | February 2024 | Allow | 7 | 0 | 1 | Yes | No |
| 18355017 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | July 2023 | July 2024 | Allow | 12 | 1 | 1 | No | No |
| 18353012 | Gene Expression System | July 2023 | August 2024 | Abandon | 13 | 1 | 1 | No | No |
| 18346099 | ANTISENSE OLIGOMERS TARGETING PCSK9 | June 2023 | May 2025 | Allow | 23 | 1 | 1 | No | No |
| 18345935 | NOVEL CRISPR ENZYMES AND SYSTEMS | June 2023 | February 2025 | Allow | 19 | 3 | 1 | Yes | No |
| 18343014 | RNA AND DNA ANALYSIS USING ENGINEERED SURFACES | June 2023 | December 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 18340192 | Conjugated Antisense Compounds for Use in Therapy | June 2023 | February 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18213116 | OLIGONUCLEOTIDES | June 2023 | June 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18336922 | NOVEL NUCLEIC ACID-GUIDED NUCLEASES | June 2023 | December 2024 | Abandon | 18 | 1 | 1 | No | No |
| 18334407 | OPTIMIZED PROTEIN LINKERS AND METHODS OF USE | June 2023 | August 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18208262 | TUNING CASCADE ASSAY KINETICS VIA MOLECULAR DESIGN | June 2023 | November 2023 | Allow | 5 | 1 | 1 | Yes | No |
| 18204383 | STAUFEN1 AGENTS AND ASSOCIATED METHODS | May 2023 | April 2025 | Allow | 23 | 2 | 1 | No | No |
| 18204329 | TUNING CASCADE ASSAY KINETICS VIA MOLECULAR DESIGN | May 2023 | November 2023 | Allow | 5 | 1 | 1 | Yes | No |
| 18320948 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | May 2023 | March 2025 | Allow | 22 | 0 | 0 | No | No |
| 18320132 | SCARLESS GENOME EDITING THROUGH TWO-STEP HOMOLOGY DIRECTED REPAIR | May 2023 | July 2025 | Allow | 25 | 1 | 0 | No | No |
| 18319977 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | May 2023 | April 2025 | Allow | 23 | 1 | 1 | No | No |
| 18316693 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | May 2023 | June 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18316981 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY | May 2023 | November 2024 | Abandon | 18 | 1 | 1 | No | No |
| 18316698 | POLYPEPTIDES USEFUL FOR GENE EDITING AND METHODS OF USE | May 2023 | August 2024 | Allow | 15 | 3 | 1 | Yes | No |
| 18315140 | CONSTRUCTION METHOD OF A TIGHT REGULATION SYSTEM FOR GENE EXPRESSION IN ZYMOMONAS MOBILIS AND APPLICATIONS | May 2023 | September 2023 | Allow | 4 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1636.
With a 37.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Art Unit 1636 is part of Group 1630 in Technology Center 1600. This art unit has examined 11,128 patent applications in our dataset, with an overall allowance rate of 54.6%. Applications typically reach final disposition in approximately 35 months.
Art Unit 1636's allowance rate of 54.6% places it in the 10% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.
Applications in Art Unit 1636 receive an average of 2.03 office actions before reaching final disposition (in the 68% percentile). The median prosecution time is 35 months (in the 18% percentile).
When prosecuting applications in this art unit, consider the following:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.